The Company has achieved a long-term viability in a rapid burst of financial milestones, adding ~$26M to the balance sheet through a series of transactions including the sale of non-core assets, a $4.6M reimbursement from BARDA contract, and a $15M public offering.
Further, PSTV is looking to divest another pipeline product candidate, DoxoPLUS, PEGylated liposomal doxorubicin, a generic version of CAELYX, used for the treatment of ovarian and breast cancers.
In 2019, the Company received positive pre-IND feedback for DocePLUS product candidate. PSTV expects to finalize Phase 2 clinical protocol in H1 2020 and treat the first patients in H2 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.